BioNTech Stock Faces A Hard Cancer Pivot Test After Q1 Loss Widens And 1,860 Jobs Are Hit
MAINZ, Germany, May 5, 2026, 13:13 CEST BioNTech announced plans Tuesday to leave several manufacturing sites, moves that could impact as many as 1,860 jobs. The biotech is also launching a buyback of up to $1 billion in its U.S.-listed shares, stepping up its reset after the pandemic as its quarterly loss grew. The Mainz-based company is sticking to its 2026 revenue target, leaning more on its cancer drug pipeline as it looks ahead.